Follow us
Business Featured

The Cannabis Business Weekly Review: U.K. Hemp Crops Destroyed, More FDA Warning Letters, Aurora’s New Contract, and more

Cannabis Business Weekly
Written by Alexandra Hicks

This week we see British crops destroyed after a hemp farm butts heads with the U.K. Home Office.

And following what seemed to be a very productive public meeting between CBD industry stakeholders and the U.S. Food and Drug Administration, the FDA sent another warning letter to well-known brand CuraLeaf. Then all the way in Israel, the medical cannabis export initiative has been delayed due to internal squabbles. All that and more in this week’s Cannabis Business Weekly Review and Newsletter.

Home office crackdown sees cannabis crop destroyed


In a show of force, the U.K. Home Office is demonstrating their strict rules by withdrawing the license of Hempen, an organic farm in Oxfordshire.  The cultivators have been forced to destroy 40 acres of their hemp, costing the business over £200,000 in lost revenue. Hempen said that in their annual declaration they admitted to illegally producing CBD for trade in the U.K. market.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

Aurora’s new contract to supply Italian medical cannabis market

aurora italy

Edmonton-based Aurora announced that it was the sole winner of the Italian government’s latest contract to supply the country with medical cannabis. Aurora beat out fellow Canadian companies Tilray, Canopy, and Wayland, as well as multiple companies from different countries. Over the next two years, Aurora will supply a minimum of 400 kilogram of medical cannabis from its Canadian EU GMP certified facilities and imported to Italy through Aurora Deutschland, its wholly-owned European subsidiary, said the company.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

The FDA just issued its newest CBD warning letter, targeting CuraLeaf

curaleaf fda

In a warning letter dated July 22, 2019, The FDA addressed multiple violations being committed by the company CuraLeaf. Does that name sound familiar to you? It should. It’s the company that secured a deal with CVS to sell CBD products in the pharmacy chain earlier this year. In the letter, the FDA referred to CuraLeaf products as “unapproved and misbranded human drugs products.”

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

Israeli medical cannabis exports delayed by internal politics

israel export

People were thrilled when the Israeli government approved a progressive new program to export medical cannabis to the international market. However, differences regarding who will control pricing between the officials at the Israeli Ministries of Health and Finance have delayed the recently-launched export initiative.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

U.S. Vape Shop Survival Depends on CBD

vape shops

The Vape Industry was so quickly becoming a permanent economic fixture in the global market moving too fast to control — often mislabeled as a “fad” by talking heads. However, vaping rapidly became not only a lifesaver, but also a lifestyle — and what’s considered my most to be a healthier lifestyle.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter


Get 30% Off The PhenoPen Premium CBD Vaping Kit

LIMITED-TIME OFFER. For people who need instant relief from their pain, insomnia, or anxiety, vaping CBD can be the ultimate solution. Vaping is believed to be safer than smoking and works faster than edibles. When you come across such a high quality product as the PhenoPen, it’s a no-brainer.

Click HERE to get your PhenoPen NOW!

Subscribe to the Recreational CBD Weekly Newsletter

A guide to finding the right CBD dose

cbd dose

While the CBD industry is growing in leaps and bounds, scientific research and studies remain lacking. One thing that nobody really has a clue about is what the right CBD dose is for which condition. For the time being, there are no specific guidelines which has patients feeling confused and frustrated.

Click here to read the full story

Click here to subscribe to the Medical Cannabis Weekly Newsletter

Have anything to add? Your voice matters! Join the conversation and contribute your insights and ideas below.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

About the author

Alexandra Hicks

Managing editor at Cannadelics and U.S based journalist, helping spread the word about the many benefits of using cannabis and psychedelics.